Dr. Ali Khaki on managing toxicities with enfortumab vedotin for bladder cancer
Ali Raza Khaki, MD, discusses managing toxicities to ensure patients can continue to receive treatment with the antibody-drug conjugate enfortumab vedotin.
Related Articles
Studies launch of copper Cu 64 PSMA I&T PET/CT in prostate cancer
Both the SOLAR-STAGE and SOLAR-RECUR trials are currently enrolling patients with prostate cancer in the US, with additional sites expected to open in Europe later…
Dr. Marhamati on initial outcomes with Aquablation in ASC setting
In this final iteration of a 3-part series, Shawn H. Marhamati, MD, MS, shares initial insights into benefits of Aquablation in an ASC environment.
2024 AUA preview: Dr. Tawagi on top research in bladder cancer
Karine Tawagi, MD, highlights several studies in bladder cancer being presented at the 2024 American Urological Association Annual Meeting.
Published OASIS trial data show safety, efficacy of Revi system for OAB
Findings from the study showed a clinical response rate of 76.4% and 78.4% at 6- and 12-months following activation of the device among patients in…
How to bill for performing complex urodynamics
“To answer this question, one must know what is and is not included in the global payment for the UDS, and the definition and instructions…
FDA approves NMIBC treatment nogapendekin alfa-inbakicept/BCG
The median duration of CR in those who experienced a response to treatment was 26.6 months (95% CI, 9.9-not reached [NR]).
Experts develop guide on online tools to reduce costs of urologic drugs
“At a time when patients are increasingly concerned about prescription drugs, this information will provide a useful starting point for making essential medications as affordable…
Dr. Haile discusses medical management of BPH
“Alpha-blockers are often, for patients, the first line of treatment because they help quickly relax the smooth muscles in the bladder and the prostate,” says…
Dr. Wolf on the CVAC System for steerable ureteroscopic renal evacuation
“I cannot overstate the impact of this device on my management of kidney stone patients,” says J. Stuart Wolf, Jr., MD, FACS.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
“This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who…